$40.13
0.74% day before yesterday
Nasdaq, Dec 27, 10:17 pm CET
ISIN
US60770K1079
Symbol
MRNA
Sector
Industry

Moderna Stock price

$40.13
-3.26 7.51% 1M
-81.05 66.88% 6M
-59.32 59.65% YTD
-60.60 60.16% 1Y
-206.75 83.75% 3Y
+20.61 105.58% 5Y
+21.53 115.75% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.30 0.74%
ISIN
US60770K1079
Symbol
MRNA
Sector
Industry

Key metrics

Market capitalization $15.44b
Enterprise Value $9.93b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.96
P/S ratio (TTM) P/S ratio 3.04
P/B ratio (TTM) P/B ratio 1.30
Revenue growth (TTM) Revenue growth -44.06%
Revenue (TTM) Revenue $5.07b
EBIT (operating result TTM) EBIT $-2.70b
Free Cash Flow (TTM) Free Cash Flow $-3.96b
Cash position $6.87b
EPS (TTM) EPS $-5.82
P/E forward negative
P/S forward 4.72
EV/Sales forward 3.03
Short interest 13.96%
Show more

Create a Free Account to create an Moderna alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Moderna Stock Analysis

Analyst Opinions

28 Analysts have issued a Moderna forecast:

10x Buy
36%
14x Hold
50%
4x Sell
14%

Analyst Opinions

28 Analysts have issued a Moderna forecast:

Buy
36%
Hold
50%
Sell
14%

Financial data from Moderna

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
5,073 5,073
44% 44%
100%
- Direct Costs 1,985 1,985
68% 68%
39%
3,088 3,088
7% 7%
61%
- Selling and Administrative Expenses 962 962
1% 1%
19%
- Research and Development Expense 4,496 4,496
8% 8%
89%
-2,370 -2,370
7% 7%
-47%
- Depreciation and Amortization 331 331
33% 33%
7%
EBIT (Operating Income) EBIT -2,701 -2,701
1% 1%
-53%
Net Profit -2,224 -2,224
36% 36%
-44%

In millions USD.

Don't miss a Thing! We will send you all news about Moderna directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Moderna Stock News

Positive
Market Watch
one day ago
Also: Technical analysis for trading in shares of Nvidia, how MicroStrategy burns cash, and tips for people with student loans in 2025
Neutral
Finbold
3 days ago
As 2024 is nearing its end, investors with a time machine are looking to visit December 2023 and take their long positions in Nvidia (NASDAQ: NVDA), Tesla (NASDAQ: TSLA), Super Micro Computer (NASDAQ: SMCI) – though with a sell order placed for April – and myriad Chinese stocks, again, with a sell order for October 1.
Neutral
GlobeNewsWire
3 days ago
The global market for mRNA vaccines and therapeutics is expanding due to the rising incidence of chronic illnesses worldwide. The global market for mRNA vaccines and therapeutics is expanding due to the rising incidence of chronic illnesses worldwide.
More Moderna News

Company Profile

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Head office United States
CEO Stéphane Bancel
Employees 5,600
Founded 2010
Website www.modernatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today